Goldman Sachs Upgrades Fulcrum Therapeutics to Buy, Announces $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Corinne Jenkins upgrades Fulcrum Therapeutics (FULC) from Neutral to Buy and sets a $15 price target.

May 13, 2024 | 8:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Goldman Sachs upgraded Fulcrum Therapeutics to Buy from Neutral and set a price target of $15, indicating a positive outlook on the stock.
Analyst upgrades, especially from reputable firms like Goldman Sachs, can significantly influence investor sentiment and stock prices. The upgrade from Neutral to Buy suggests a strong confidence in the company's future performance and growth potential. The announcement of a $15 price target further supports this positive outlook, potentially leading to increased investor interest and a short-term rise in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100